AKR1B10 and hepatocellular carcinoma: Although epalrestat may be harmful to CRC HCT-8 cells by promoting DNA damage [73], it enhances the efficacy of sorafenib (an anti-cancer drug) on HCC by inhibiting AKR1B10 [167].